Mineralys to Present Lorundrostat Trial Data in November
The company will share key findings from the Transform-HTN hypertension trial at the American Heart Association sessions.
Updated on Sept. 23, 2026 in Heart Disease
Live Poll
Do you believe developing new targeted enzyme inhibitors is the right way to treat chronic hypertension?
Mineralys Therapeutics is scheduled to present results from the Transform-HTN study on November 8, 2026, in Chicago. The trial evaluates lorundrostat, an experimental treatment for patients with hypertension.
Why it matters
Elevated blood pressure is a major driver of cardiovascular risks such as heart attacks and strokes. Innovations in treatment are critical given the significant death toll and economic impact associated with hypertension in the United States.
Lorundrostat, which has a 10-12 hour half-life, showed a 40-70% reduction in plasma aldosterone concentration during trials. Approximately 30% of hypertensive patients are estimated to have dysregulated levels of this hormone.
The players
Mineralys Therapeutics
A clinical-stage biopharmaceutical company headquartered in Radnor, Pa., that focuses on developing treatments for hypertension.
Manish Saxena
A lead researcher associated with the clinical development of lorundrostat.
The details
Lorundrostat functions as an aldosterone synthase inhibitor by targeting the CYP11B2 enzyme. The ongoing Transform-HTN study is an open-label extension trial aimed at assessing the safety, efficacy, and tolerability of the drug in hypertensive participants.
Timeline
September 23, 2026: Mineralys Therapeutics announced the upcoming data presentation.
November 6-9, 2026: American Heart Association Scientific Sessions 2026 take place.
November 8, 2026: Manish Saxena will present the Transform-HTN trial data.
The Big Picture
The upcoming presentation follows the standard pattern of pharmaceutical companies using the American Heart Association Scientific Sessions as a platform to share clinical progress.
The development of new aldosterone synthase inhibitors could eventually provide a new treatment pathway for the significant portion of hypertensive patients who struggle with hormone dysregulation. Patients should continue current prescribed therapies and consult their doctors regarding any new medication options.
The takeaway
Hypertension remains a leading health challenge in the U.S. that claims hundreds of thousands of lives annually. Ongoing clinical research into targeted enzyme inhibitors highlights the medical community's continued effort to reduce the burden of chronic heart disease.
Further reading
For more information on cardiovascular research, visit our section on Heart Disease.
More information
Review additional details on the company pipeline via Mineralys Therapeutics corporate information.
Live Poll
Do you believe developing new targeted enzyme inhibitors is the right way to treat chronic hypertension?
